Meng-Yu Zhang

Dr. Meng-Yu Zhang

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2026 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
YWYu Wang
Yu Wang
MZMeng-Yu Zhang
Meng-Yu Zhang
LFLijun Fang
Lijun Fang
JQJiajia Qu
Jiajia Qu
CHChen Huo
Chen Huo
YQYiqing Qu
Yiqing Qu
PRKD1 is downregulated in non-small-cell lung cancer (NSCLC). Whether and how PRKD1 regulates tumorigenesis and metastasis is previously unknown. Here, we report that PRKD1 negatively regulates β-catenin protein abundance. PRKD1 promotes ubiquitination and degradation of EIF5A. EIF5A upregulates β-catenin and activates the Wnt signaling pathway. Thus, the PRKD1/EIF5A/β-catenin axis modulates the Wnt signaling pathway in NSCLC. Functionally, PRKD1 inhibits cell proliferation and metastasis both in vitro and in vivo. PRKD1 is downregulated and EIF5A is upregulated in NSCLC. Lower PRKD1 and higher EIF5A predict a worse patient survival. Our study suggests that the PRKD1/EIF5A/β-catenin axis is involved in the carcinogenesis of NSCLC and may serve as a new therapeutic target for NSCLC.